

DIASORIN S.P.A. TO ACQUIRE THE "MUREX" PRODUCT LINE

The DiaSorin Group announced today that it has entered into a binding agreement with Abbott to purchase its MUREX product line. This transaction is consistent with DiaSorin's strategy to continue to add new depth to its product portfolio, further strengthen its leadership position in infectious disease and open the door for attractive growth opportunities in the future.

Saluggia (Vercelli, Italy), March 10, 2010 – DiaSorin S.p.A., a global leader in the immunodiagnosics market, announced it has entered into a binding agreement for the acquisition of the assets concerning the MUREX® product line from Abbott.

The MUREX product line consists of products for the diagnosis of HIV, HCV and HBV infections. MUREX products are manufactured at two plants located in the UK and South Africa. These two manufacturing facilities are included in the transaction. MUREX products generated approximately \$66.7 mill for the year ended December 31, 2009. The transaction does not include commercial payables and receivables that will remain with the seller.

The purchase price is \$58 million cash and it will be funded entirely with internal Company resources.

The acquisition is expected to close in the second quarter of 2010 but remains subject to customary closing conditions.

Commenting on the agreement, Carlo Rosa, CEO, of DiaSorin said "We are very pleased to acquire the MUREX product line which is a brand with a strong reputation for quality and reliability. The market for HCV/HIV/HBV testing is currently valued at over \$1billion and DiaSorin is planning to enter this market with its Liaison XL. With the acquisition of the MUREX assays we will be well positioned to enter this market both through continued sales of existing products in the ELISA format, and through developing the MUREX assays for our Liaison XL platform"



About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 20 companies based in Europe, the United States, Central and South America and Asia. It has more than 1,100 employees, including about 110 research and development specialists, and operates four manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA) and Dublin (Ireland). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which it operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.diasorin.it

Contacts:

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02